Abstract:Rationale: Short QT syndrome (SQT) is a rare but arrhythmogenic disorder featured by shortened ventricular repolarization and a propensity toward life-threatening ventricular arrhythmias and sudden cardiac death. Objective: This study aimed to investigate the single-cell mechanism of SQT using patient-specific and gene-corrected induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Methods and Results: One SQT patient carrying missense mutation T618I in potassium voltage-gated channel subfamily H member 2 (KCNH2) was recruited as well as 2 healthy control subjects in this study. Control and SQT patient-specific iPSCs were generated from skin fibroblasts using nonintegrated Sendai virus. The KCNH2 T618I mutation was corrected by genome editing in SQT iPSC lines to generate isogenic controls. All iPSCs were differentiated into iPSC-CMs using monolayer-based differentiation protocol. SQT iPSC-CMs exhibited abnormal action potential phenotype featured by shortened action potential duration and increased beat-beat interval variability, when compared with control and gene-corrected iPSC-CMs. Furthermore, SQT iPSC-CMs showed KCNH2 gain-of-function with increased rapid delayed rectifying potassium current (IKr) density and enhanced membrane expression. Gene expression profiling of iPSC-CMs exhibited a differential cardiac ion-channel gene expression profile of SQT. Moreover, QTc of SQT patient and action potential durations of SQT iPSC-CMs were both normalized by quinidine, indicating that quinidine is beneficial to KCNH2 T618I of SQT. Importantly, shortened action potential duration phenotype observed in SQT iPSC-CMs was effectively rescued by a short-peptide scorpion toxin BmKKx2 with a mechanism of targeting KCNH2. Conclusions: We demonstrate that patient-specific and gene-corrected iPSC-CMs are able to recapitulate single-cell phenotype of SQT, which is caused by the gain-of-function mutation KCNH2 T618I. These findings will help elucidate the mechanisms underlying SQT and discover therapeutic drugs for treating the disease by using peptide toxins as lead compounds.

Establishment of human embryonic stem cell lines carrying LQT1 mutations by CRISPR base editing

Genome Editing of Isogenic Human Induced Pluripotent Stem Cells Recapitulates Long QT Phenotype for Drug Testing.

Generation of an Induced Pluripotent Stem Cell Line from a Long QT Syndrome Patient Carrying KCNH2/1956C > A Mutation.

Establishment of human embryonic stem cell WAe009-A-74 carrying a Long QT syndrome mutation in KCNH2

Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome

Establishment of Human Embryonic Stem Cell WAe009-A-48 Carrying a Long QT Syndrome Mutation in SCN5A.

Generation of a TRPV1 Knockout Human Pluripotent Stem Cell Line (Wae009-a-u) Using CRISPR/Cas9.

Generation of a KCNJ11 Homozygous Knockout Human Embryonic Stem Cell Line WAe001-A-12 Using CRISPR/Cas9.

Generation of KCNH2 heterozygous knockout induced pluripotent stem cell (iPSC) line (Long and Short QT Syndrome)

Establishment of a human-induced pluripotent stem cell line from a long QT syndrome type 2 patient harboring a KCNH2 mutation

Base Editing of Human Pluripotent Stem Cells for Modeling Long QT Syndrome

GW29-e0632 Pathogenic Mechanism and Gene Correction for LQTS-causing Double-Mutations in KCNQ1 Using Pluripotent Stem Cell Model

KCNQ1-deficient and KCNQ1-mutant human embryonic stem cell-derived cardiomyocytes for modeling QT prolongation

Pathogenic Mechanism And Gene Correction For Lqts-Causing Double- Mutations In Kcnq1 Using Pluripotent Stem Cell Model

Induced pluripotent stem cell model from urine epithelial cells of patient with long QT syndrome

Generation of Three Ipsc Lines (Xachi007-A, XACHi008-A, XACHi009-A) from a Chinese Family with Long QT Syndrome Type 5 with Heterozygous C.226g>a (p.d76n) Mutation in KCNE1gene.

Generation of a Human Induced Pluripotent Stem Cell Line from a Female Patient Carrying LZTR1 Gene Mutation

Base Editing Mediated Generation of Point Mutations Into Human Pluripotent Stem Cells for Modeling Disease

Establishment and characterization of ZJUCHi003: an induced pluripotent stem cell line from a patient with Temple–Baraitser/Zimmermann–Laband syndrome carrying KCNH1 c.1070G > A (p.R357Q) variant

Mutations in conserved amino acids in the KCNQ1 channel and risk of cardiac events in type-1 long-QT syndrome.

Modeling long QT syndrome type 2 on-a-chip via in-depth assessment of isogenic gene-edited 3D cardiac tissues